Novartis’ Cosentyx shows benefits for ankylosing spondylitis and psoriatic arthritis

Novartis' interleukin-17A inhibitor therapy Cosentyx has demonstrated its effectiveness as a treatment for both ankylosing spondylitis and psoriatic arthritis in new clinical studies.

Findings from the MEASURE 1 extension study showed that Cosentyx delivered sustained improvements in the signs and symptoms of active ankylosing spondylitis at three years, consistent with previous findings for active psoriatic arthritis.

Meanwhile, a two-year post-hoc analysis of the FUTURE 2 study showed that by week three of treatment, half of the patients treated with Cosentyx reported clinically meaningful improvements in pain of over 20 percent.

At week four, the proportion of patients reporting no pain or discomfort was greater for Cosentyx than for placebo, with this gap continuing to increase through to week 104.

Vas Narasimhan, global head of drug development and chief medical officer at Novartis, said: "We are pleased that Cosentyx continues to provide sustained benefits for patients with psoriasis, psoriatic arthritis and ankylosing spondylitis."

Cosentyx is the only IL-17A inhibitor approved for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis, with more than 80,000 patients treated in the post-marketing setting worldwide across all indications.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.